MCID: BCL002
MIFTS: 48

B Cell Deficiency

Categories: Blood diseases, Rare diseases, Immune diseases

Aliases & Classifications for B Cell Deficiency

MalaCards integrated aliases for B Cell Deficiency:

Name: B Cell Deficiency 12 14
Immunoglobulin Heavy Chain Deficiency 12 56 69
Immunoglobulin Heavy Chain Deletion 12
B Cell Deficiencies 12
Humoral Immune Defect 69

Classifications:

Orphanet: 56  
Rare immunological diseases


External Ids:

Disease Ontology 12 DOID:2115
ICD9CM 35 279.03
SNOMED-CT 64 190982008
Orphanet 56 ORPHA169110
UMLS via Orphanet 70 C0398692
ICD10 via Orphanet 34 D80.8
UMLS 69 C0154276

Summaries for B Cell Deficiency

Disease Ontology : 12 A primary immunnodeficiency disease that is caused by a lack of infection-fighting antibody producing B cells (immunoglobulins) or B cells that are not functioning properly.

MalaCards based summary : B Cell Deficiency, also known as immunoglobulin heavy chain deficiency, is related to immunoglobulin alpha deficiency and b cell linker protein deficiency. An important gene associated with B Cell Deficiency is IGLL1 (Immunoglobulin Lambda Like Polypeptide 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Selenium and Iron have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are hematopoietic system and immune system

Related Diseases for B Cell Deficiency

Diseases related to B Cell Deficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 151)
id Related Disease Score Top Affiliating Genes
1 immunoglobulin alpha deficiency 30.5 AICDA CD40 CD40LG CD79A
2 b cell linker protein deficiency 30.5 CD40LG CD79A TGM2 TNFRSF13B
3 arteriosclerosis 29.4 BTK CD19 CD40LG CD79A
4 agammaglobulinemia 11.1
5 agnathia-microstomia-synotia 10.8 CD79A IGLL1
6 red-green color blindness 10.8 CD79A IGLL1
7 primary central nervous system lymphoma 10.8 TNFRSF13B TNFRSF13C
8 alcoholic neuropathy 10.7 CD40LG CD79A
9 calloso-genital dysplasia 10.7 CD40LG CD79A
10 lambda 5 deficiency 10.7
11 autoimmune lymphoproliferative syndrome, type iii 10.7
12 agammaglobulinemia, x-linked 1 10.7
13 variola major 10.7 CD40LG CD79A
14 mu chain disease 10.7 CD40LG CD79A
15 rabies 10.7 CD40LG CD79A
16 familial retinoblastoma 10.7 CD40LG CD79A
17 anti-basement membrane glomerulonephritis 10.7 CD40LG CD79A
18 microinvasive cervical squamous cell carcinoma 10.7 CD40LG CD79A
19 fetal erythroblastosis 10.7 CD40LG CD79A
20 spinal canal and spinal cord meningioma 10.7 CD40LG CD79A
21 trichostrongyloidiasis 10.7 CD40LG CD79A
22 leukodystrophy 10.7 CD40LG CD79A
23 heart septal defect 10.7 CD40LG CD79A
24 cryptorchidism arachnodactyly mental retardation 10.7 CD40LG CD79A
25 acute kidney tubular necrosis 10.7 CD40LG CD79A
26 secretory meningioma 10.7 CD40LG CD79A
27 hodgkin's lymphoma, nodular sclerosis 10.7 CD40LG CD79A
28 imperforate oropharynx-costo vetebral anomalies 10.7 CD40LG CD79A
29 malignant otitis externa 10.7 CD40LG CD79A
30 benign epilepsy with centrotemporal spikes 10.6 CD40LG CD79A
31 tongue cancer 10.6 CD40LG CD79A
32 hydrops of gallbladder 10.6 CD40LG CD79A
33 gamma heavy chain disease 10.6 CD40LG CD79A
34 rosacea conjunctivitis 10.6 CD40LG CD79A
35 viral meningitis 10.6 CD40LG CD79A
36 alopecia areata 10.6 CD40LG CD79A
37 kidney carcinoma in situ 10.6 CD40LG CD79A
38 cardiac tuberculosis 10.6 CD40LG CD79A
39 dumping syndrome 10.6 CD40LG CD79A
40 leiomyosarcoma 10.6 CD40LG CD79A
41 generalized atherosclerosis 10.6 CD40LG CD79A
42 cerebral neuroblastoma 10.6 CD40LG CD79A
43 pancreatic vasoactive intestinal peptide producing tumor 10.6 CD40LG CD79A
44 retinal microaneurysm 10.5 CD40LG CD79A IGLL1
45 aniseikonia 10.5 CD40LG CD79A
46 scrotum basal cell carcinoma 10.5 CD19 CD40LG
47 breast medullary carcinoma 10.5 CD27 CD79A
48 diabetic macular edema 10.5 CD40LG CD79A IGLL1
49 diabetic angiopathy 10.5 BTK CD40LG CD79A
50 chronic mucocutaneous candidiasis 10.5 CD40LG CD79A

Graphical network of the top 20 diseases related to B Cell Deficiency:



Diseases related to B Cell Deficiency

Symptoms & Phenotypes for B Cell Deficiency

MGI Mouse Phenotypes related to B Cell Deficiency:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.24 AICDA BTK CD19 CD27 CD40 CD40LG
2 immune system MP:0005387 10.16 AICDA BTK CD19 CD27 CD40 CD40LG
3 cellular MP:0005384 10.14 CD19 CD27 CD40LG CD79A IDS NFKB2
4 homeostasis/metabolism MP:0005376 10.13 CD40LG CD79A CR2 NFKB2 PRKCD SH2D1A
5 mortality/aging MP:0010768 9.9 AICDA BTK CD19 CD40LG CR2 IDS
6 neoplasm MP:0002006 9.43 TGM2 TNFRSF13B AICDA BTK CD19 CD79A
7 renal/urinary system MP:0005367 9.32 CD19 CD40 CD40LG CD79A CR2 NFKB2

Drugs & Therapeutics for B Cell Deficiency

Drugs for B Cell Deficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 374)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selenium Approved, Vet_approved Phase 4 7782-49-2
2
Iron Approved Phase 4,Phase 2,Phase 3,Phase 1 7439-89-6 23925
3
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
5
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
6
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
7
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
8
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
9
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
10
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 1 53-03-2 5865
11
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154598-52-4 64139
12
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
13
Lopinavir Approved Phase 4,Phase 3,Phase 2 192725-17-0 92727
14
Nevirapine Approved Phase 4,Phase 3,Phase 2 129618-40-2 4463
15
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2 155213-67-5 392622
16
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
17
Zidovudine Approved Phase 4,Phase 1 30516-87-1 35370
18
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1 616-91-1 12035
19
Cysteamine Approved, Investigational Phase 4 60-23-1 6058
20
Hydroxocobalamin Approved Phase 4,Phase 2,Phase 3 13422-51-0 11953898 5460373 44475014
21
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
22
Nitric Oxide Approved Phase 4,Phase 2 10102-43-9 145068
23
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Early Phase 1 50-14-6 5280793
24
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 1406-16-2
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
26
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 143 6006
27
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Early Phase 1 67-97-0 6221 10883523 5280795
28
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 2,Phase 3 68-19-9 44176380
29 Antioxidants Phase 4,Phase 3,Phase 2,Phase 1
30 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Antacids Phase 4,Phase 2,Phase 1
34 Anti-Ulcer Agents Phase 4,Phase 2,Phase 1
35 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
36
Proton pump inhibitors Phase 4
37 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Early Phase 1
38 Ergocalciferols Phase 4,Phase 3,Phase 2,Early Phase 1
39 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Antibodies Phase 4,Phase 2,Phase 3,Phase 1
42 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
43 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Liver Extracts Phase 4,Phase 3,Phase 1
47 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1
48 Cortisol succinate Phase 4
49 Hydrocortisone 17-butyrate 21-propionate Phase 4
50 Hydrocortisone acetate Phase 4

Interventional clinical trials:

(show top 50) (show all 286)

id Name Status NCT ID Phase Drugs
1 Selenium Supplementation in Pregnancy Unknown status NCT01465867 Phase 4
2 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4 omeprazole
3 Immunologic Action of a Single Dose Cholecalciferol Completed NCT01845142 Phase 4 single administration of 100.000 I.U. vitamin D;Placebo
4 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
5 Immunologic Memory (Supp. of ATN 024) Completed NCT00142753 Phase 4
6 Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV-infected Women Completed NCT01812980 Phase 4
7 PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial Completed NCT01192035 Phase 4 Efavirenz or Nevirapine;Ritonavir-boosted lopinavir
8 Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis Completed NCT00028262 Phase 4 Cystagon
9 Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients Completed NCT00441688 Phase 4 GI265235
10 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
11 Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome. Recruiting NCT02031289 Phase 4 Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
12 Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females Active, not recruiting NCT01031069 Phase 4
13 Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease Terminated NCT00775606 Phase 4 Lopinavir 400 mg/ritonavir 100 mg;Efavirenz
14 N-Acetylcysteine and Arginine Administration in Diabetic Patients Terminated NCT00569465 Phase 4 Arginine;Acetylcysteine;Placebo
15 Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01623024 Phase 3 Vitamin D
16 Modified Dose and Schedule of Recombinant Hepatitis B Vaccination in HIV-infected Adult Subjects Unknown status NCT01289106 Phase 3
17 Vitamin B12 Supplementation During Pregnancy Completed NCT01795131 Phase 2, Phase 3
18 A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma Completed NCT00000658 Phase 3 Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Allopurinol;Methotrexate;Cytarabine;Leucovorin calcium;Sargramostim;Dexamethasone
19 Low-dose Iron Supplementation and Markers of Iron Status Among Non-anemic, Iron-deficient Women Completed NCT02683369 Phase 2, Phase 3
20 Immunological and Clinical Responses to Zinc in Children With Diarrhoea Completed NCT00408356 Phase 3 Zinc
21 Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents Completed NCT00075907 Phase 3 Efavirenz + 2 NRTIs;Lopinavir/Ritonavir + 2 NRTIs
22 Effects of Low-dose Complex B-vitamins on Homocysteine and Framingham Risk Score Among Chinese Elderly Completed NCT00755664 Phase 3
23 Efficacy and Mechanisms of GLN Dipeptide in the SICU Completed NCT00248638 Phase 3 Glutamine dipeptide with 15% Clinisol;15% Clinisol
24 Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Completed NCT01495702 Phase 3 NNRTI;FTC/TDF;Stribild
25 Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, Completed NCT01475838 Phase 3 PI;RTV;FTC/TDF;Stribild
26 Stopping Postpartum Vitamin A Supplementation: Missing Concealed Benefit Completed NCT02043223 Phase 2, Phase 3
27 Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig Recruiting NCT03211065 Phase 2, Phase 3 20% subcutaneous immunoglobulin
28 A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma Recruiting NCT03078855 Phase 3
29 Vitamin B12 Supplementation During Pregnancy on Cognitive Development Recruiting NCT03071666 Phase 2, Phase 3
30 Pharmacokinetics, Safety, and Efficacy of Cobicistat-boosted Atazanavir or Cobicistat-boosted Darunavir in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects Recruiting NCT02016924 Phase 2, Phase 3 ATV;DRV;Cobicistat;BR
31 Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair Recruiting NCT02912559 Phase 3 Atezolizumab;Fluorouracil;Leucovorin Calcium;Oxaliplatin
32 Vitamin B12, Neurodevelopment and Growth in Nepal Active, not recruiting NCT02272842 Phase 2, Phase 3
33 IV Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania Active, not recruiting NCT02541708 Phase 3 Ferric carboxymaltose;Ferrous sulfate + folic acid
34 Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children Active, not recruiting NCT01854775 Phase 2, Phase 3 E/C/F/TAF
35 Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants Active, not recruiting NCT01923311 Phase 2, Phase 3 EVG;Background regimen
36 Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women Active, not recruiting NCT01705574 Phase 3 E/C/F/TDF;RTV;ATV;FTC/TDF;E/C/F/TDF Placebo;RTV Placebo;ATV Placebo;FTC/TDF Placebo;E/C/F/TAF
37 Immune Responses in Patients Treated With Raltegravir Withdrawn NCT00785967 Phase 3
38 Effect of Vitamin A Supplementation on Immune Responses in Human Neonates Unknown status NCT01476358 Phase 2
39 The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP) Unknown status NCT00937131 Phase 2 Rituximab
40 Ingested Interferon Alpha: Prolongation or Permanence of the "Honeymoon" Phase in Newly Diagnosed Type 1 Diabetes Mellitus Unknown status NCT00005665 Phase 2 interferon alpha
41 Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma Unknown status NCT01516593 Phase 2 Induction Phase;Consolidation Phase (on day +50);Intensification phase;BEAM conditioning
42 Trial of E10A in Head and Neck Cancer Unknown status NCT00634595 Phase 2 E10A;Cisplatin;Paclitaxel
43 Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura Completed NCT00907751 Phase 2 rituximab
44 An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclita Completed NCT01618136 Phase 1, Phase 2 E7449 alone;E7449 plus TMZ;E7449 plus carboplatin and paclitaxel
45 A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes Completed NCT00001438 Phase 2 all-trans-retinoic acid with IFN-alpha2a
46 MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID Completed NCT00794508 Phase 2
47 Oral Vitamin B12 Administration for Vitamin B12 Deficiency After Total Gastrectomy Completed NCT00699478 Phase 2 mecobalamin
48 Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV) Completed NCT01228318 Phase 2 Zoledronic acid
49 A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL Completed NCT00799136 Phase 2 R-EPOCH and cART
50 Growth Hormone to Increase Immune Function in People With HIV Completed NCT00071240 Phase 2 Somatropin (recombinant human growth hormone)

Search NIH Clinical Center for B Cell Deficiency

Genetic Tests for B Cell Deficiency

Anatomical Context for B Cell Deficiency

MalaCards organs/tissues related to B Cell Deficiency:

39
B Cells, Bone, Bone Marrow, T Cells, Lung, Liver, Kidney

Publications for B Cell Deficiency

Articles related to B Cell Deficiency:

(show top 50) (show all 53)
id Title Authors Year
1
Comprehensive validation of T- and B-cell deficiency in rag1-null zebrafish: Implication for the robust innate defense mechanisms of teleosts. ( 28790360 )
2017
2
Progressive severe B cell deficiency in pediatric Rubinstein-Taybi syndrome. ( 27825976 )
2016
3
Mutation of Fnip1 is associated with B-cell deficiency, cardiomyopathy, and elevated AMPK activity. ( 27303042 )
2016
4
NK and B cell deficiency in a MPS type II family with novel mutation in the IDS gene. ( 25038527 )
2014
5
Additional B-cell deficiency does not affect growth and angiogenesis of ectopic human endometrium in T-cell-deficient endometriosis mouse models during long-term culture. ( 25270508 )
2014
6
Generation of recombination activating gene-1-deficient neonatal piglets: a model of T and B cell deficient severe combined immune deficiency. ( 25437445 )
2014
7
Autosomal-dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in nonprocessable p100. ( 25237204 )
2014
8
B-cell deficiency and severe autoimmunity caused by deficiency of protein kinase C I'. ( 23319571 )
2013
9
A case of IgM deficiency with B cell deficiency detected by ABO discrepancy in a patient with acute osteomyelitis. ( 23667850 )
2013
10
B cell deficient mice are protected from biliary obstruction in the rotavirus-induced mouse model of biliary atresia. ( 23991203 )
2013
11
Novel spontaneous deletion of artemis exons 10 and 11 in mice leads to T- and B-cell deficiency. ( 24069355 )
2013
12
T and B cell deficiency associated with yellow nail syndrome. ( 21995335 )
2012
13
More on NK-cell and B-cell deficiency with a thymic mass. ( 21591963 )
2011
14
NK-cell and B-cell deficiency with a thymic mass. ( 21306273 )
2011
15
Chronic B cell deficiency from birth prevents age-related alterations in the B lineage. ( 21810615 )
2011
16
Long-term immune deficiency after allogeneic stem cell transplantation: B-cell deficiency is associated with late infections. ( 20133894 )
2010
17
B cell-deficient NOD.H-2h4 mice have CD4+CD25+ T regulatory cells that inhibit the development of spontaneous autoimmune thyroiditis. ( 16446379 )
2006
18
Effects of combined T- and B-cell deficiency on murine ischemia reperfusion injury. ( 15888022 )
2005
19
Mucosal B cell deficiency in IgA-/- mice abrogates the development of allergic lung inflammation. ( 16002732 )
2005
20
B-cell deficiency and reduced B-cell reconstitution in hemoglobin-deficit mice. ( 14662329 )
2003
21
B cell deficiency confers protection from renal ischemia reperfusion injury. ( 12960350 )
2003
22
Successful immunosuppressive therapy with cyclosporine A for posthepatitis B-cell deficiency with activated cytoplasmic interferon--gamma-positive T-lymphocytes. ( 11999357 )
2002
23
B-cell deficiency and type 1 diabetes. ( 11858222 )
2002
24
A case of severe B cell deficiency after allogeneic stem cell transplantation. ( 12235525 )
2002
25
B-cell deficiency and type 1 diabetes. ( 11844863 )
2002
26
Novel Igalpha (CD79a) gene mutation in a Turkish patient with B cell- deficient agammaglobulinemia. ( 11920841 )
2002
27
B-cell deficiency suppresses vaccine-induced protection against murine filariasis but does not increase the recovery rate for primary infection. ( 11598082 )
2001
28
Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. ( 11591325 )
2001
29
B-Cell deficiency predisposes mice to disseminating anaerobic infections: protection by passive antibody transfer. ( 10992465 )
2000
30
A quantitative-trait locus controlling peripheral B-cell deficiency maps to mouse Chromosome 15. ( 11003386 )
2000
31
Severe B cell deficiency in mice lacking the tec kinase family members Tec and Btk. ( 11104803 )
2000
32
Resistance to herpetic stromal keratitis in immunized B-cell-deficient mice. ( 10208930 )
1999
33
Antigen-induced airway hyperresponsiveness, pulmonary eosinophilia, and chemokine expression in B cell-deficient mice. ( 10030835 )
1999
34
Microphthalmic mice display a B cell deficiency similar to that seen for mast and NK cells. ( 10586063 )
1999
35
The effect of B cell deficiency on the immune response to acetylcholine receptor and the development of experimental autoimmune myasthenia gravis. ( 9646836 )
1998
36
Mutations in the human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia. ( 9419212 )
1998
37
Severe B cell deficiency and disrupted splenic architecture in transgenic mice expressing the E41K mutated form of Bruton's tyrosine kinase. ( 9736610 )
1998
38
Requirements for allergen-induced airway hyperreactivity in T and B cell-deficient mice. ( 9642684 )
1998
39
B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization. ( 9794370 )
1998
40
B cell-deficient muMT mice as an experimental model for Mycoplasma infections in X-linked agammaglobulinemia. ( 9295053 )
1997
41
A pronounced thymic B cell deficiency in the spontaneously diabetic BB rat. ( 9164980 )
1997
42
Analysis of T cell receptor V beta gene expression in B cell deficient mice after experimental herpes simplex virus keratitis. ( 9385402 )
1997
43
Alloantibody- and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis: lack of progression to sclerotic lesions in B cell-deficient mice. ( 9415552 )
1997
44
B-cell deficiency does not abrogate development of cutaneous hyperplasia in mice inheriting the defective fibrillin-1 gene. ( 9451590 )
1997
45
Exhaustion of CTL memory and recrudescence of viremia in lymphocytic choriomeningitis virus-infected MHC class II-deficient mice and B cell-deficient mice. ( 8816417 )
1996
46
The Yaa gene-dependent B-cell deficiency worsens the generalized lymphadenopathy and autoimmunity of C57BL/6-gld male mice. ( 7835973 )
1994
47
The resolution of acute malaria in a definitive model of B cell deficiency, the JHD mouse. ( 8157969 )
1994
48
Intestinal intraepithelial gamma/delta T cells in B-cell deficiency. ( 8167738 )
1993
49
B cell deficiency progresses with lineage maturation in nude.X-linked immunodeficient mice B cell deficiency progresses with lineage maturation. ( 1385525 )
1992
50
Chronic giardiasis in B-cell-deficient mice expressing the xid gene. ( 3262587 )
1988

Variations for B Cell Deficiency

Expression for B Cell Deficiency

Search GEO for disease gene expression data for B Cell Deficiency.

Pathways for B Cell Deficiency

Pathways related to B Cell Deficiency according to GeneCards Suite gene sharing:

(show all 26)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 BTK CD19 CD27 CD40 CD40LG CD79A
2
Show member pathways
13.27 CD27 CD40 CD40LG NFKB2 PRKCD TNFRSF13B
3
Show member pathways
13.26 BTK CD27 CD40 CD40LG PRKCD TLR9
4
Show member pathways
13.19 BTK CD27 CD40 CD40LG PRKCD TNFRSF13B
5
Show member pathways
13.1 BTK CD19 CD40 CD79A CR2 PRKCD
6
Show member pathways
12.76 AICDA CD40 CD40LG TNFRSF13B TNFRSF13C
7
Show member pathways
12.55 CD40 CD40LG NFKB2 PRKCD TLR9 TNFRSF13C
8
Show member pathways
12.54 CD27 CD40 CD40LG CR2 PRKCD
9
Show member pathways
12.53 BTK CD40 CD40LG CD79A NFKB2
10
Show member pathways
12.47 BTK CD19 CD79A CR2 NFKB2
11
Show member pathways
12.45 BTK CD27 CD40 CD40LG PRKCD TLR9
12 12.35 AICDA BTK CD19 CD40LG CD79A NFKB2
13
Show member pathways
12.32 CR2 NFKB2 TNFRSF13B TNFRSF13C
14
Show member pathways
12.25 BTK CD19 CD79A CR2 PRKCD
15
Show member pathways
12.24 BTK CD19 CD40 PRKCD
16 12.21 CD19 CD40 CR2 NFKB2
17 11.96 CD19 CD40 CD40LG SH2D1A
18
Show member pathways
11.83 BTK CD19 CD79A
19 11.78 BTK CD40 CD40LG NFKB2 TNFRSF13C
20
Show member pathways
11.7 CD27 CD40 CD40LG TNFRSF13B TNFRSF13C
21
Show member pathways
11.6 CD40 CD40LG NFKB2 TNFRSF13B
22 11.54 CD27 CD40 CD40LG
23 11.48 CD40 CD40LG CR2 TLR9 TNFRSF13B TNFRSF13C
24 11.42 CD40 CD40LG TLR9
25 11.16 CD19 CD27 CD40 CD40LG CR2 TNFRSF13B
26 10.84 AICDA BTK CD19 CD40 CD40LG CD79A

GO Terms for B Cell Deficiency

Cellular components related to B Cell Deficiency according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.73 BTK CD19 CD27 CD40 CD40LG CD79A
2 external side of plasma membrane GO:0009897 9.23 CD19 CD27 CD40 CD40LG CD79A IGLL1

Biological processes related to B Cell Deficiency according to GeneCards Suite gene sharing:

(show all 25)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.96 CD27 CD40 CD40LG CR2 IGLL1
2 innate immune response GO:0045087 9.95 BTK CR2 IGLL1 NFKB2 SH2D1A TLR9
3 inflammatory response GO:0006954 9.93 CD27 CD40 CD40LG NFKB2 TLR9
4 cell surface receptor signaling pathway GO:0007166 9.88 CD19 CD27 CD79A TNFRSF13B
5 defense response to bacterium GO:0042742 9.85 AICDA IGLL1 PRKCD TLR9
6 adaptive immune response GO:0002250 9.8 BTK CD79A SH2D1A TNFRSF13B TNFRSF13C
7 platelet activation GO:0030168 9.79 CD40 CD40LG PRKCD
8 regulation of immune response GO:0050776 9.77 CD19 CD40 CD40LG SH2D1A TNFRSF13C
9 B cell receptor signaling pathway GO:0050853 9.73 BTK CD19 CD79A IGLL1
10 B cell activation GO:0042113 9.67 BTK CD40 CD79A
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.65 BTK CD40 CD40LG NFKB2 TLR9
12 positive regulation of interleukin-12 production GO:0032735 9.63 CD40 CD40LG TLR9
13 B cell homeostasis GO:0001782 9.62 TNFRSF13B TNFRSF13C
14 B cell differentiation GO:0030183 9.62 AICDA CD40LG CD79A CR2
15 negative regulation of B cell proliferation GO:0030889 9.61 BTK TNFRSF13B
16 isotype switching GO:0045190 9.61 AICDA CD40LG
17 positive regulation of endothelial cell apoptotic process GO:2000353 9.6 CD40 CD40LG
18 positive regulation of B cell differentiation GO:0045579 9.59 BTK CD27
19 positive regulation of interferon-gamma biosynthetic process GO:0045078 9.58 TLR9 TNFRSF13C
20 immunoglobulin mediated immune response GO:0016064 9.57 CD27 PRKCD
21 immune system process GO:0002376 9.56 BTK CD40 CD79A CR2 SH2D1A TLR9
22 tumor necrosis factor-mediated signaling pathway GO:0033209 9.55 CD27 CD40 CD40LG TNFRSF13B TNFRSF13C
23 regulation of immunoglobulin secretion GO:0051023 9.52 CD40 CD40LG
24 positive regulation of B cell proliferation GO:0030890 9.51 CD40 TNFRSF13C
25 B cell proliferation GO:0042100 9.02 CD40 CD40LG CD79A CR2 PRKCD

Molecular functions related to B Cell Deficiency according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 8.92 CD27 CD79A CR2 TLR9

Sources for B Cell Deficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....